Welcome to VIRTTU
VIRTTU Biologics is a clinical stage biotechnology company pioneering the transformative development of viruses for therapeutic purposes to create life-saving treatments for cancer.
The Company’s strength is built on that most valuable of assets – the knowledge that the technology works and is safe in patients.
By remodeling a common virus we have developed and patented a series of medicines that have the potential to transform treatment and target many forms of cancer effectively.
Our most advanced product, a unique cancer-destroying (oncolytic) virus, has the potential to radically change oncology therapy through its potent ability to seek out and multiply only in cancer cells: destroying them whilst leaving healthy cells unaffected.
We are now actively progressing the clinical development programme required to secure regulatory approval to market our lead product, SEPREHVIR®, for use in cancer therapy.
Products
VIRTTU's lead product SEPREHVIR®, a "First in Class" oncolytic virus, shows broad utility against a range of difficult to treat cancers.
Advice and Support for Patients
If you are suffering from any form of cancer or know anyone that is, click here for links to organisations that offer advice and support.